‘‘(i) experience managing clinical or 
research programs focused on pathogenic 
mechanisms and biological pathways re-
lated to Long COVID; and 
‘‘(ii) demonstrated commitment to ad-
dressing Long COVID and other infection- 
associated chronic conditions, such as 
myalgic encephalomyelitis/chronic fatigue 
syndrome, postural orthostatic tachycardia 
syndrome, and post-treatment Lyme dis-
ease syndrome/persistent Lyme disease. 
‘‘(B) CONSULTATION.—In appointing the 
Director under subparagraph (A), the Secretary 
shall consult with independent, patient-led orga-
nizations or advocacy groups representing Long 
COVID patients and their families. 
‘‘(2) RESPONSIBILITIES.—The Director of the 
Program shall— 
‘‘(A) act as the primary Federal official 
with responsibility for coordinating all Long 
COVID research conducted or supported by the 
National Institutes of Health; 
‘‘(B) represent the National Institutes of 
Health Long COVID Research Program at all 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
relevant Executive branch task force meetings 
and committees; and 
‘‘(C) maintain communication with all rel-
evant Federal departments and agencies to en-
sure the timely transmission of information con-
cerning advances in Long COVID research and 
the clinical treatment of Long COVID and 
other infection-associated chronic conditions be-
tween such departments and agencies, and for 
dissemination to affected communities and 
health care providers. 
‘‘(c) ACTIVITIES.—The Program shall— 
‘‘(1) investigate the etiology, pathophysiology, 
risk factors, and pathology of Long COVID in 
adults and children; 
‘‘(2) explore the best ways to prevent, detect, 
monitor, manage, and treat Long COVID in adults 
and children; 
‘‘(3) contribute knowledge to the under-
standing, prevention, mitigation, management, and 
treatment of Long COVID; 
‘‘(4) develop and facilitate programs on Long 
COVID, within the National Institutes of Health 
and in other settings; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(5) conduct comparative research to under-
stand the similarities and differences between Long 
COVID and other infection-associated chronic condi-
tions with similar phenotypes, such as myalgic 
encephalomyelitis/chronic fatigue syndrome, postural 
orthostatic tachycardia syndrome, and post-treat-
ment Lyme disease syndrome/persistent Lyme dis-
ease, and how activities funded by the Program 
could improve understanding of such other condi-
tions; and 
‘‘(6) conduct comparative research to under-
stand the similarities and differences between Long 
COVID and severe, long-term effects from COVID– 
19 vaccinations. 
‘‘(d) DUTIES.— 
‘‘(1) INTERAGENCY
COORDINATION
OF
LONG 
COVID ACTIVITIES.—The Director of the Program 
shall coordinate with the national research institutes 
and national centers, as appropriate, on Long 
COVID research. In carrying out this paragraph, 
the Director of the Program shall evaluate the Long 
COVID activities of each such institute or center 
and shall provide for the periodic reevaluation of 
such activities. 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(2) CONSULTATION.—The Director of the Pro-
gram shall carry out all duties, including the devel-
opment of the research plan under section 499B–1 
in consultation with the heads of the national re-
search institutes and national centers, with the advi-
sory councils of such institutes and centers, and with 
the Long COVID Research Program Advisory Board 
established under section 499B–4. 
‘‘(e) NON-DUPLICATION OF EFFORT.—The Director 
shall ensure that activities carried out under this section 
do not unnecessarily duplicate the efforts of other Federal 
departments or agencies. 
‘‘SEC. 499B–1. LONG COVID RESEARCH PLAN. 
‘‘(a) IN GENERAL.—Not later than 1 year after the 
date of enactment of the Long COVID Research Moonshot 
Act, the Director of the Program established under section 
499B shall develop and make public a comprehensive re-
search plan for the conduct and support of all Long 
COVID research activities of the national research insti-
tutes and national centers. The Director of the Program 
shall update such plan annually. 
‘‘(b) CONTENTS.—The research plan developed under 
subsection (a) shall— 
‘‘(1) identify current Long COVID research 
conducted or supported by the national research in-
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
stitutes and national centers, opportunities and 
needs for additional research, including among pa-
tients who face the highest disease burden and pedi-
atric patients, and priorities for such research; 
‘‘(2) evaluate the progress of Long COVID re-
search against strategic priorities, goals, and objec-
tives, identified in previous versions of the research 
plan; 
‘‘(3) make recommendations for the coordina-
tion of such research conducted or supported by the 
National Institutes of Health and other agencies of 
the Federal Government; and 
‘‘(4) include goals and objectives of the Pro-
gram for conducting, supporting, and coordinating 
Long COVID research. 
‘‘(c) REQUIREMENTS.—In developing the research 
plan under subsection (a), the Director of the Program 
shall— 
‘‘(1) ensure that the plan establishes priorities 
among Long COVID research that the Program is 
authorized to carry out; 
‘‘(2) ensure that the plan establishes objectives 
regarding such research and describes the means for 
achieving the objectives; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(3) ensure that all amounts appropriated for 
such research under section 499B–6 are expended in 
accordance with the plan; 
‘‘(4) review the plan not less frequently than 
annually, and revise the plan as appropriate to 
prioritize funding and research relative to scientific 
urgency; 
‘‘(5) ensure that the plan serves as a broad, 
binding statement of policies regarding Long 
COVID research of the National Institutes of 
Health, but does not affect the responsibility of any 
of the national research institutes or centers with re-
spect to the programs or projects of such institutes 
and centers; and 
‘‘(6) annually prepare and submit to the Direc-
tor of NIH for review and transmittal by the Direc-
tor of NIH to the President and to Congress a 
budget estimate for carrying out the plan for the up-
coming fiscal year. 
‘‘(d) CONSULTATION.—In developing, implementing, 
reviewing, and prioritizing elements of the research plan 
under this section, the Director of the Program shall con-
sult, as appropriate with— 
‘‘(1) representatives of other Federal agencies 
involved in Long COVID research, including the 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
Centers for Disease Control and Prevention, the 
Agency for Healthcare Research and Quality, and 
the Administration for Community Living; 
‘‘(2) the Long COVID Research Advisory 
Board established under section 499B–4; 
‘‘(3) the Office of Long COVID Research and 
Practice of the Department of Health and Human 
Services; 
‘‘(4) leading scientific experts on Long COVID; 
and 
‘‘(5) independent, patient-led organizations or 
advocacy groups representing patients with Long 
COVID and other infection-associated chronic condi-
tions with similar phenotypes, and the families of 
such patients. 
‘‘(e) REPORT.—The Director of the Program shall 
submit the research plan developed under subsection (a), 
and updates to such plan, to— 
‘‘(1) the Committee on Health, Education, 
Labor, and Pensions of the Senate; 
‘‘(2) the Committee on Energy and Commerce 
of the House of Representatives; 
‘‘(3) the Secretary; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(4) the Office of Long COVID Research and 
Practice of the Department of Health and Human 
Services; and 
‘‘(5) the Director of NIH, who shall post the 
plan, and updates to the plan, on the website of the 
National Institutes of Health. 
‘‘SEC. 499B–2. EXPEDITED LONG COVID RESEARCH. 
‘‘(a) IN GENERAL.—The Director of NIH shall estab-
lish a process to expedite the award of grants, contracts, 
and cooperative agreements for research projects con-
ducted or supported by the National Institutes of Health 
and relating to Long COVID. 
‘‘(b) REQUIREMENTS
FOR
MAKING
EXTERNAL 
FUNDING AVAILABLE.—With respect to programs of 
grants, contracts, and cooperative agreements described in 
subsection (a), the Director of NIH shall— 
‘‘(1) make publicly available the deadlines for 
submitting applications for such programs, and en-
sure that such deadlines provide applicants with suf-
ficient time from the date of the announcement for 
such grant, contract, and cooperative agreement to 
submit an application; 
‘‘(2) ensure that applicants receive a final deci-
sion on their applications within 120 days of submis-
sion; and 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(3) with respect to applications that are de-
nied, provide a written explanation to the applicant 
on the reasons for the denial. 
‘‘(c) EVALUATION
OF GRANT APPLICATIONS.—In 
making a determination to award a grant, contract, and 
cooperative agreement for research projects described in 
subsection (a), the Director of NIH shall— 
‘‘(1) give priority to research that— 
‘‘(A) tests the outcomes of existing drug 
and device interventions in patients with Long 
COVID; 
‘‘(B) focuses on identifying interventions 
for pediatric patients with Long COVID; 
‘‘(C) aids in the development of new inter-
ventions that have evidence to suggest effective-
ness in treating or curing Long COVID; or 
‘‘(D) includes institutions that represent, 
or have a successful track record of providing 
equitable care or services to, historically under-
served communities; 
‘‘(2) consider research that has the ability to 
begin interventions in a timely manner; 
‘‘(3) consider research that uses decentralized 
trials or remote monitoring techniques for data col-
lection; and 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(4) consider research that includes patients 
with other infection-associated chronic conditions 
with 
similar 
phenotypes, 
such 
as 
myalgic 
encephalomyelitis/chronic fatigue syndrome, postural 
orthostatic tachycardia syndrome, and post-treat-
ment Lyme disease syndrome/persistent Lyme dis-
ease. 
‘‘(d) REASONABLE PRICING.—In awarding contracts, 
grants, and cooperative agreements for research projects 
described in subsection (a) that relates to the development 
of a drug or device for the potential treatment or manage-
ment of Long COVID, or identifying a new indication or 
use specific to the treatment or management of Long 
COVID in a drug or device that is already approved or 
cleared by the Food and Drug Administration, the Direc-
tor of NIH shall include terms and conditions requiring 
that the price of such a drug or device for purposes of 
procurement by the Federal Government or if sold on the 
commercial market, whether procured from, or sold by, the 
recipient of such Federal award or another person— 
‘‘(1) is fair and reasonable, taking into ac-
count— 
‘‘(A) the value of the drug and device to 
the public health, including the impact of the 
price on access to the drug or device; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(B) the costs incurred by the Federal 
Government in research and development of the 
drug or device; 
‘‘(C) the costs incurred by the recipient of 
the award in research and development of the 
drug or device, and the costs of manufacturing 
such drug or device; 
‘‘(D) whether the drug or device provided 
a significant improvement in health outcomes, 
compared to other therapies available at the 
time of its approval or authorization; 
‘‘(E) the cumulative expected global reve-
nues generated by the drug or device; and 
‘‘(F) other factors, as the Secretary deter-
mines appropriate; and 
‘‘(2) does not exceed the lowest price charged 
for such drug or device, among Canada, France, 
Germany, Italy, Japan, and the United Kingdom. 
‘‘(e) CONSULTATION.—In making a determination to 
award a grant, contract, or cooperative agreement for re-
search projects relating to Long COVID, the Director of 
NIH shall consult with the Long COVID Research Advi-
sory Board. Members of the Long COVID Research Advi-
sory Board shall provide a recommendation on any final 
funding decisions. If the Director of NIH makes a decision 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
that is different than the recommendation, the Director 
of NIH shall provide a written justification for the deci-
sion within 5 days. 
‘‘SEC. 499B–3. SCIENTIFIC REVIEW GROUP. 
‘‘(a) IN GENERAL.—In order to ensure high quality, 
rigorous scientific review of applications for grants, con-
tracts, and cooperative agreements described in section 
499B–2(a), consistent with section 492, the Director of 
NIH shall establish a scientific review group on Long 
COVID and other infection-associated chronic conditions, 
and shall convene a group of leading scientific experts to 
serve on such group, for terms of up to 5 years. 
‘‘(b) DUTIES.—The scientific research group shall 
conduct an initial review of applications for grants, con-
tracts, and other cooperative agreements described in sec-
tion 499B–2(a), and submit a funding recommendation to 
the Director of NIH for final determination. 
‘‘SEC. 499B–4. LONG COVID RESEARCH PROGRAM ADVISORY 
BOARD. 
‘‘(a) IN GENERAL.—The Director of NIH shall estab-
lish the Long COVID Research Program Advisory Board 
(referred to in this section as the ‘Advisory Board’). 
‘‘(b) MEMBERSHIP.— 
‘‘(1) IN GENERAL.—The Advisory Board shall 
be comprised of 18 members, including appointed 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
members and nonvoting ex officio members, as fol-
lows: 
‘‘(A) The Secretary shall conduct a nomi-
nation process that allows for public input on 
nominees. The Secretary shall appoint nomi-
nated individuals, giving particular consider-
ation to individuals from backgrounds that rep-
resent the diversity of the Long COVID popu-
lation, with an emphasis on patients who face 
the highest disease burden. Individuals so ap-
pointed shall include the following: 
‘‘(i) 10 members who are scientists, 
physicians, and other health care profes-
sionals, who are not officers or employees 
of the Federal Government, and who have 
primary expertise in Long COVID and 
other infection-associated chronic condi-
tions, with consideration given to such in-
dividuals with expertise in pediatric popu-
lations. 
‘‘(ii) 5 members who live with Long 
COVID. 
‘‘(iii) 1 member who is a caregiver to 
an individual with Long COVID. 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(iv) 2 members who are employed by 
the National Institutes of Health and have 
expertise in Long COVID research. 
‘‘(B) The following shall be ex officio mem-
bers of the Advisory Board: 
‘‘(i) A representative of the Long 
COVID Research Program established 
under section 499. 
‘‘(ii) A representative of the National 
Institutes of Health. 
‘‘(iii) A representative of the National 
Institutes of Neurological Disorders and 
Stroke. 
‘‘(iv) A representative of the National 
Heart, Lung, and Blood Institute. 
‘‘(v) A representative of the National 
Institute of Allergy and Infectious Dis-
eases. 
‘‘(vi) A representative of the Office of 
the Assistant Secretary for Health. 
‘‘(vii) A representative of the Centers 
for Disease Control and Prevention. 
‘‘(viii) A representative of the Admin-
istration for Community Living. 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00016
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(ix) A representative of the Agency 
for Healthcare Research and Quality. 
‘‘(x) Representatives of any other 
agency or office of the Department of 
Health and Human Services that the Sec-
retary determines appropriate for the Advi-
sory Board to carry out its function. 
‘‘(2) ENGAGEMENT WITH ORGANIZATIONS.—In 
appointing individuals to the Advisory Board, the 
Secretary shall engage with leading scientific experts 
on Long COVID and independent, patient-led orga-
nizations of advocacy groups representing Long 
COVID patients. 
‘‘(c) COMPENSATION.—Ex officio members of the Ad-
visory Board who are officers or employees of the Federal 
Government shall not receive any compensation for service 
on the Advisory Board. Non-Federal members of the Advi-
sory Board may receive, for each day (including travel 
time) they are engaged in the performance of the functions 
of the advisory committee, compensation at rates not to 
exceed the daily equivalent to the annual rate of basic pay 
for level III of the Executive Schedule under section 5314 
of title 5, United States Code. 
‘‘(d) TERMS.—The term of office of an appointed 
member of the Advisory Board is 5 years. Any member 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
appointed to fill a vacancy for an unexpired term shall 
be appointed for the remainder of such term. A member 
may serve after the expiration of the member’s term until 
a successor has taken office. If a vacancy occurs in the 
Advisory Board, the Secretary shall make an appointment 
to fill the vacancy not later than 60 days from the date 
the vacancy occurred. 
‘‘(e) CHAIR.—The members of the Advisory Board 
shall select a chair from among the appointed members. 
The term of the Office of Chair shall be 2 years. 
‘‘(f) MEETINGS.— 
‘‘(1) IN GENERAL.—The Advisory Board shall 
meet at the call of the chairman or upon request of 
the Director of the Program established under sec-
tion 499B, but not less often than monthly in the 
first year after establishment, then not less often 
than 6 times a year for each subsequent year. The 
meetings of the Advisory Board may be held vir-
tually. 
‘‘(2) PURPOSE.—Of the meetings held, one or 
more shall be held to address research priorities of 
the National Institutes of Health relating to Long 
COVID. 
‘‘(3) PUBLICATION
OF
SUMMARY.—For each 
meeting held, the Director of NIH shall post on the 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
website of the National Institutes of Health a sum-
mary of the proceedings. 
‘‘(g) DUTIES.—The Advisory Board shall, subject to 
the direction and supervision of the Director of NIH— 
‘‘(1) review, approve, and evaluate the imple-
mentation of the research plan issued under section 
499B–1, and advise in updating the plan; 
‘‘(2) provide guidance to the Director of the 
Program established under section 499B with re-
spect to appropriate research activities to be under-
taken regarding the clinical treatment of Long 
COVID, which may include— 
‘‘(A) research on interventions for pre-
venting, treating, and understanding the mech-
anisms of Long COVID; 
‘‘(B) research on the effectiveness of treat-
ing Long COVID with drugs that are not yet 
approved by the Food and Drug Administration 
for the treatment of Long COVID; 
‘‘(C) reviewing ongoing publicly- and pri-
vately-supported research on treatments for 
Long COVID; 
‘‘(D) issue and make available to health 
care professionals and the public reports de-
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
scribing and evaluating research described in 
subparagraphs (A), (B), and (C); and 
‘‘(E) convene accessible meetings for the 
purpose of determining the recommendations 
which may inform development of clinical guide-
lines by health care provider organizations; and 
‘‘(3) engage in other necessary activities to con-
tribute to the National Institutes of Health’s overall 
research priorities related to Long COVID, and en-
sure accountability, transparency, and communica-
tion of results of the Program established under sec-
tion 499B. 
‘‘SEC. 499B–5. DATA SYSTEM AND CLEARINGHOUSE ON RE-
SEARCH INFORMATION. 
‘‘(a) DATA SYSTEM.— 
‘‘(1) IN GENERAL.—The Director of the Na-
tional Institutes of Health, in consultation with the 
Director of the Program established under section 
499B and the Director of the National Library of 
Medicine shall establish, maintain, and operate a 
data system for the collection, storage, analysis, re-
trieval, and timely dissemination of primary data re-
garding research on Long COVID that is conducted 
or supported by the Program. Information from the 
data system shall be available through information 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
systems available to health care professionals and 
providers, researchers, and members of the public. 
‘‘(2) REGISTRY.— 
‘‘(A) IN GENERAL.—The data system es-
tablished under paragraph (1) shall include a 
registry of clinical trials of experimental treat-
ments that have been developed for research on 
Long COVID. Such registry shall include infor-
mation on patient eligibility criteria, including 
the definition of Long COVID, and, as applica-
ble, demographic information, including sex, 
age, disability status, ethnicity, and race, and 
the location of the trial site or sites. 
‘‘(B) SUBMISSION
OF
INFORMATION.— 
Principal investigators of trials described in 
subparagraph (A) shall provide such informa-
tion to the registry not later than 30 days after 
public announcement of the clinical trial. Once 
a trial has been completed, the principal investi-
gator shall provide the registry with information 
pertaining to the results, including potential 
toxicities or adverse effects associated with the 
experimental treatment or treatments evalu-
ated. 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(C) PUBLIC AVAILABILITY.—The registry 
described in this paragraph shall be made avail-
able to researchers and the general public, in a 
machine-readable format. 
‘‘(b) CLEARINGHOUSE.—The Director of NIH, in 
consultation with the Director of the Program and with 
the National Library of Medicine, shall establish, main-
tain, and operate a program to provide information on re-
search and prevention activities of the national research 
institutes that relate to research on Long COVID. 
‘‘SEC. 499B–6. APPROPRIATIONS. 
‘‘For purposes of carrying out this part, there are ap-
propriated, out of amounts in the Treasury not otherwise 
appropriated, $1,000,000,000 for each of fiscal years 
2025 through 2034, to remain available until expended.’’. 
TITLE II—PUBLIC HEALTH RE-
SEARCH, SURVEILLANCE AND 
RELATED ACTIVITIES 
SEC. 201. LONG COVID PROGRAMS. 
Title III of the Public Health Service Act (42 U.S.C. 
241 et seq.) is amended by adding at the end the fol-
lowing: 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00022
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘PART X—LONG COVID ACTIVITIES 
‘‘SEC. 399PP. PUBLIC HEALTH SURVEILLANCE OF LONG 
COVID AND INFECTION-ASSOCIATED CHRON-
IC CONDITIONS. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, shall establish or continue, as applicable, surveil-
lance activities to better understand the burden and sever-
ity of Long COVID and related infection-associated chron-
ic conditions, with specific consideration given to vulner-
able populations, such as children. In carrying out this 
section, the Secretary shall— 
‘‘(1) collect data on the incidence, prevalence, 
and severity of Long COVID and related infection- 
associated chronic conditions; 
‘‘(2) monitor for Long COVID and Long 
COVID-like conditions, as appropriate, to enable 
early intervention and identification of factors asso-
ciated with severity of symptoms; 
‘‘(3) compile, and make publicly available, in 
accessible formats, Long COVID data collected 
under paragraph (1); 
‘‘(4) develop and disseminate best practices for 
conducting surveillance for State, local, and Tribal 
public health officials, and other relevant public 
health stakeholders; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00023
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(5) provide technical assistance to inter-
national organizations, as applicable, regarding the 
monitoring of Long COVID; and 
‘‘(6) conduct additional surveillance activities, 
as the Secretary determines appropriate, to better 
understand the burden and severity of Long COVID. 
‘‘(b) AUTHORIZATION
OF
APPROPRIATIONS.—For 
purposes of carrying out this section, there are authorized 
to be appropriated $32,000,000 for each of fiscal years 
2025 through 2034. 
‘‘SEC. 399PP–1. PUBLIC HEALTH PROGRAMMING. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, shall make grants to State, local, and Tribal 
health departments for the purpose of carrying out activi-
ties related to Long COVID. 
‘‘(b) USE
OF FUNDS.—A State, local, or Tribal 
health department that receives a grant under subsection 
(a) may use funds received through such grant to— 
‘‘(1) provide training on the identification of 
Long COVID to clinicians, public health experts, 
and other relevant health care professionals; 
‘‘(2) link individuals with Long COVID to care, 
as appropriate and applicable; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00024
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(3) support the development and dissemination 
of public information and educational materials on 
Long COVID, including materials to address misin-
formation and disinformation; 
‘‘(4) support laboratory capacity for screening 
and diagnosis of Long COVID and associated symp-
toms; and 
‘‘(5) build, maintain, and sustain jurisdiction- 
level infrastructure related to preparedness for post- 
infectious syndromes. 
‘‘(c) AUTHORIZATION
OF
APPROPRIATIONS.—For 
purposes of carrying out this section, there are authorized 
to be appropriated $45,000,000 for each of fiscal years 
2025 through 2034. 
‘‘SEC. 399PP–2. NATIONAL PUBLIC EDUCATION CAMPAIGN 
ON LONG COVID. 
‘‘(a) IN GENERAL.—The Secretary, acting through 
the Director of the Centers for Disease Control and Pre-
vention, and in collaboration with national, State, local, 
and Tribal public health partners, shall develop a public 
education campaign for patients, families, and caregivers 
to educate and increase awareness about Long COVID in 
children and adults. Such campaign shall include informa-
tion on— 
‘‘(1) the signs and symptoms of Long COVID; 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00025
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
‘‘(2) how to prevent and seek treatment for 
Long COVID; 
‘‘(3) self-management tools and support serv-
ices; and 
‘‘(4) other topics, as the Secretary determines 
appropriate. 
‘‘(b) CONSULTATION.—In developing materials for 
the campaign, the Secretary shall consult with inde-
pendent, patient-led organizations or advocacy groups rep-
resenting Long COVID patients and their families and 
other relevant stakeholders. 
‘‘(c) ACCESSIBILITY.—The public education cam-
paign under this section shall be made available in mul-
tiple languages, including American Sign Language. 
‘‘(d) AUTHORIZATION
OF
APPROPRIATIONS.—For 
purposes of carrying out this section, there are authorized 
to be appropriated $21,500,000 for each of fiscal years 
2025 through 2029. 
‘‘SEC. 399PP–3. PROVIDER EDUCATION. 
‘‘(a) IN GENERAL.—The Secretary shall— 
‘‘(1) develop and make publicly available best 
practices for coordinated, multidisciplinary care for 
individuals with Long COVID; 
‘‘(2) develop, update, as appropriate, and make 
publicly available clinical guidance and provider edu-
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00026
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
cation materials, including for providers working 
with pediatric populations; and 
‘‘(3) facilitate provider education on Long 
COVID signs, symptoms, maintenance, and treat-
ment, including through technology-enabled collabo-
rative learning. 
‘‘(b) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there are authorized 
to be appropriated $3,000,000 for each of fiscal years 
2025 through 2034.’’. 
SEC. 202. REHABILITATION RESEARCH AND TRAINING CEN-
TER ON LONG COVID AMONG PEOPLE WITH 
DISABILITIES. 
(a) IN GENERAL.—Section 240(b)(2)(C) of the Reha-
bilitation Act of 1973 (29 U.S.C. 764(b)(2)(C)) is amend-
ed— 
(1) in clause (v), by striking ‘‘; and’’ and insert-
ing a semicolon; 
(2) in clause (vi), by striking the period and in-
serting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(vii) applied research regarding evi-
dence-based treatments, services, and sup-
ports for individuals with disabilities with 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00027
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
Long COVID or other infection-associated 
chronic conditions.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out the amendment made by subsection (b), there are au-
thorized to be appropriated to the Director of the National 
Institute on Disability, Independent Living, and Rehabili-
tation Research, $10,000,000 for the period of fiscal years 
2025 through 2029. 
SEC. 203. CLINICAL OUTCOMES ASSESSMENTS. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Commissioner of 
Food and Drugs, shall establish or continue the develop-
ment and validation of clinical outcomes assessments to 
support regulatory decision making for drugs, including 
biological products, and devices used to treat Long 
COVID. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For pur-
poses of carrying out this section, there are authorized to 
be appropriated $9,000,000 for each of fiscal years 2025 
through 2034. 
SEC. 204. ELECTRONIC REPORTING FORM. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Commissioner of 
Food and Drugs, shall establish or continue the develop-
ment, refinement, and maintenance of a Long COVID 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00028
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
electronic reporting form for patients to identify current 
treatments and treatments under development for Long 
COVID. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For pur-
poses of carrying out this section, there are authorized to 
be appropriated $16,600,000 for each of fiscal years 2025 
through 2034. 
SEC. 205. LONG COVID CARE NETWORK. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, acting through the Director of the Agen-
cy for Healthcare Research and Quality, shall develop, or 
continue to support, multidisciplinary Long COVID clinics 
to provide access to comprehensive, coordinated care for 
individuals with Long COVID, particularly underserved 
populations that are disproportionately impacted by the 
effects of Long COVID. 
(b) AUTHORIZATIONS
OF
APPROPRIATIONS.—For 
purposes of carrying out this section, there are authorized 
to be appropriated $10,000,000 for each of fiscal years 
2025 through 2034. 
SEC. 206. RESEARCH ON LONG COVID BEST PRACTICES. 
(a) IN GENERAL.—The Secretary of Health and 
Human Services, in coordination with the Director of the 
Agency for Healthcare Research and Quality, shall de-
velop, test, synthesize, and disseminate best practices and 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00029
Fmt 6652
Sfmt 6201
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB
decision support tools related to the clinical care organiza-
tion, delivery, and integration of clinical and social services 
for Long COVID and other infection-associated chronic 
conditions. 
(b) AUTHORIZATION OF APPROPRIATIONS.—For the 
purposes of carrying out this section, there are authorized 
to be appropriated $10,000,000 for each of fiscal years 
2025 through 2034. 
Æ 
VerDate Sep 11 2014 
01:41 Oct 22, 2024
Jkt 059200
PO 00000
Frm 00030
Fmt 6652
Sfmt 6301
E:\BILLS\H9907.IH
H9907
kjohnson on DSK7ZCZBW3PROD with $$_JOB